NASDAQ:IDXX

IDEXX Laboratories - IDXX Stock Forecast, Price & News

$485.51

+6.77 (+1.41%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $471.61
▼
$485.71
50-Day Range: $454.86
▼
$514.59
52-Week Range: $317.06
▼
$560.92

Volume: 268,172 shs
Average Volume: 383,173 shs
Market Capitalization: $40.25 billion

P/E Ratio: 60.46
Dividend Yield: N/A
Price Target: $520.63

Institutional Ownership

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 7.2% Upside
$520.63 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -2.80
Upright™ Environmental Score
News Sentiment: 1.01
Based on 10 Articles This Week
Insider Trading: Selling Shares
$1.51 M Sold Last Quarter
Proj. Earnings Growth: 11.06%
From $9.58 to $10.64 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

306th out of 1,005 stocks

Diagnostic Substances Industry

5th out of 15 stocks

2.4

Analyst's Opinion

Consensus Rating
IDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $520.63, IDEXX Laboratories has a forecasted upside of 7.2% from its current price of $485.51.
Amount of Analyst Coverage
IDEXX Laboratories has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for IDXX.

0.0

Dividend Strength

Dividend Yield
IDEXX Laboratories does not currently pay a dividend.
Dividend Growth
IDEXX Laboratories does not have a long track record of dividend growth.

2.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IDEXX Laboratories has received a 20.02% net impact score from Upright. Idexx Laboratories seems to create the most significant positive value in categories "Taxes", "Nutrition", and "Jobs". The positive contribution in the "Nutrition" impact category is mostly driven by its "Veterinary x-rays", "Veterinary hematology analyzers", and "Veterinary services for livestock" products. See details.
Environmental Sustainability
The Environmental Impact score for IDEXX Laboratories is -2.80.

3.3

News and Social Media Coverage

News Sentiment
IDEXX Laboratories has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for IDEXX Laboratories this week, compared to 5 articles on an average week.
Search Interest
Only 28 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
MarketBeat Follows
12 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,514,220.00 in company stock.
Percentage Held by Insiders
Only 2.06% of the stock of IDEXX Laboratories is held by insiders.
Percentage Held by Institutions
87.90% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for IDEXX Laboratories are expected to grow by 11.06% in the coming year, from $9.58 to $10.64 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEXX Laboratories is 60.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 109.70.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEXX Laboratories is 60.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 68.17.
Price to Earnings Growth Ratio
IDEXX Laboratories has a PEG Ratio of 2.78. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
IDEXX Laboratories has a P/B Ratio of 66.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, a

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

March 26, 2023 | americanbankingnews.com

IDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $590.00 at Morgan Stanley

March 23, 2023 | markets.businessinsider.com

Analyst Expectations for IDEXX Laboratories's Future

March 26, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 

March 18, 2023 | finance.yahoo.com

These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well

March 18, 2023 | americanbankingnews.com

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $514.75 Average Target Price from Analysts

March 17, 2023 | marketwatch.com

IDEXX Laboratories Inc. stock rises Thursday, outperforms market

March 15, 2023 | benzinga.com

$1000 Invested In IDEXX Laboratories 5 Years Ago Would Be Worth This Much Today

March 14, 2023 | finance.yahoo.com

The total return for IDEXX Laboratories (NASDAQ:IDXX) investors has risen faster than earnings growth over the last five years

March 26, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

March 13, 2023 | msn.com

What Does IDEXX Laboratories' Debt Look Like?

March 8, 2023 | nasdaq.com

Why Is Idexx (IDXX) Down 6.6% Since Last Earnings Report?

March 6, 2023 | benzinga.com

A Look Into IDEXX Laboratories' Debt

March 6, 2023 | finance.yahoo.com

Should You Investigate IDEXX Laboratories, Inc. (NASDAQ:IDXX) At US$488?

March 2, 2023 | benzinga.com

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

March 1, 2023 | marketwatch.com

IDEXX Laboratories Inc. stock outperforms market on strong trading day

March 1, 2023 | finance.yahoo.com

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

February 27, 2023 | finance.yahoo.com

IDEXX (IDXX) Global Sales, Instrument Placement Robust

February 24, 2023 | finance.yahoo.com

Zacks Industry Outlook Highlights Edwards Lifesciences, IDEXX Laboratories and Hologic

February 23, 2023 | thestreet.com

Idexx Reaches New 52-Week High (IDXX)

February 23, 2023 | msn.com

Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?

February 23, 2023 | finance.yahoo.com

Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?

February 23, 2023 | finance.yahoo.com

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

February 21, 2023 | msn.com

Elanco drives animal health stocks lower as 2023 guidance disappoints

February 20, 2023 | finance.yahoo.com

Groundbreaking IDEXX Study Reveals Opportunities to Increase Veterinary Practice Productivity

February 16, 2023 | finance.yahoo.com

We Think IDEXX Laboratories (NASDAQ:IDXX) Can Stay On Top Of Its Debt

February 12, 2023 | finance.yahoo.com

IDEXX Laboratories' (NASDAQ:IDXX) investors will be pleased with their strong 166% return over the last five years

February 10, 2023 | finance.yahoo.com

2 Top Stocks I'm Buying Hand Over Fist in February

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings: 2/06/2023
Today: 3/26/2023
Next Earnings (Estimated): 5/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:IDXX
CUSIP: 45168D10
CIK: 874716
Web: www.idexx.com
Phone: (207) 556-0300
Fax: 207-556-4346
Employees: 10,780
Year Founded: 1983

Price Target and Rating

Average Stock Price Forecast: $520.63
High Stock Price Forecast: $600.00
Low Stock Price Forecast: $415.00
Forecasted Upside/Downside: +7.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $8.03
Trailing P/E Ratio: 60.46
Forward P/E Ratio: 50.68
P/E Growth: 2.76
Net Income: $679.09 million
Net Margins: 20.17%
Pretax Margin: 25.54%
Return on Equity: 124.51%
Return on Assets: 25.66%

Debt

Debt-to-Equity Ratio: 1.14
Current Ratio: 0.89
Quick Ratio: 0.59

Sales & Book Value

Annual Sales: $3.37 billion
Price / Sales: 11.95
Cash Flow: $9.76 per share
Price / Cash Flow: 49.74
Book Value: $7.35 per share
Price / Book: 66.06

Miscellaneous

Outstanding Shares: 82,900,000
Free Float: 81,195,000
Market Cap: $40.25 billion
Optionable: Optionable
Beta: 1.18

Social Links

Key Executives

Jonathan J. Mazelsky
President, Chief Executive Officer & Director

John Hart
Senior Vice President-Global Operations

Brian Patrick McKeon
Chief Financial Officer, Treasurer & Executive VP

Ken Grady
Chief Information Officer & Senior VP

Murthy Yerramilli
Senior Vice President-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.
What is IDEXX Laboratories' stock price forecast for 2023?: 8 Wall Street analysts have issued 12 month price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $600.00. On average, they expect the company's share price to reach $520.63 in the next twelve months. This suggests a possible upside of 7.2% from the stock's current price.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.
How have IDXX shares performed in 2023?: IDEXX Laboratories' stock was trading at $407.96 at the beginning of the year. Since then, IDXX shares have increased by 19.0% and is now trading at $485.51.
View the best growth stocks for 2023 here.
When is IDEXX Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our IDXX earnings forecast.
How were IDEXX Laboratories' earnings last quarter?: IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its earnings results on Monday, February, 6th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.13. The company earned $828.60 million during the quarter, compared to the consensus estimate of $820.91 million. IDEXX Laboratories had a trailing twelve-month return on equity of 124.51% and a net margin of 20.17%. The company's revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.89 earnings per share.
Read the conference call transcript.
What ETFs hold IDEXX Laboratories' stock?: ETFs with the largest weight of IDEXX Laboratories (NASDAQ:IDXX) stock in their portfolio include ProShares Pet Care ETF (PAWZ), Sterling Capital Focus Equity ETF (LCG), First Trust Water ETF (FIW), Invesco DWA Healthcare Momentum ETF (PTH), iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ) and QRAFT AI-Enhanced U.S. Large Cap Momentum ETF (AMOM).
What guidance has IDEXX Laboratories issued on next quarter's earnings?: IDEXX Laboratories issued an update on its FY 2023 earnings guidance on Monday, February, 6th. The company provided EPS guidance of $9.27-$9.75 for the period, compared to the consensus earnings per share estimate of $9.50. The company issued revenue guidance of $3.59 billion-$3.69 billion, compared to the consensus revenue estimate of $3.62 billion.
What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?: 40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).
What is IDEXX Laboratories' stock symbol?: IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
Who are IDEXX Laboratories' major shareholders?: IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Moneta Group Investment Advisors LLC (8.99%), Fundsmith LLP (4.16%), Alliancebernstein L.P. (3.91%), Bamco Inc. NY (2.87%), Geode Capital Management LLC (2.32%) and American Century Companies Inc. (1.82%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends.
How do I buy shares of IDEXX Laboratories?: Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IDEXX Laboratories' stock price today?: One share of IDXX stock can currently be purchased for approximately $485.51.
How much money does IDEXX Laboratories make?: IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $40.25 billion and generates $3.37 billion in revenue each year. The company earns $679.09 million in net income (profit) each year or $8.03 on an earnings per share basis.
How many employees does IDEXX Laboratories have?: The company employs 10,780 workers across the globe.
How can I contact IDEXX Laboratories?: IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IDEXX Laboratories - IDXX Stock Forecast, Price & News

IDEXX Laboratories MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDXX Stock News Headlines

IDXX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

IDXX Stock - Frequently Asked Questions

Overall MarketRank^™